News OverviewLife Science NewsLife Science News OverviewBiochemistry NewsBiomaterials NewsBiophysics NewsBiotechnology NewsCancer & Oncology NewsCell Biology NewsComputational Biology NewsGenetics & Genomics NewsImmunology NewsImmunology NewsAllergy Research NewsAntibody Research NewsAutoimmunity Research NewsImmune System Research NewsImmunohistochemistry Research NewsInflamation Research NewsLife Science NewsMedical & Biomedical Research NewsMicrobiology NewsMolecular Biology NewsNeuroscience NewsPharmaceutical Sciences NewsMicro, Nano & Nano Bio NewsOther Related News
If you find nanogolive usefull, become a Guest Author
• Editorial Articles: If you have recently published a paper about Antibody Research or have exciting material to share with the scientific community, contact us for publishing.
• Collaboration with our Life Science Glossary of scientific terms: You can write definitions of scientific in the scope of Antibody Research for publishing.
As a Guest Author of nanogolive, your global visibility will increase.
Contact the Editor.
|
|
Antibody Research News
Recommendation: to enjoy more comfortably your navigation experience on nanogolive, please place the cursor over the new story of your interest, right-click and select "open in new tab". Following this procedure, you have the advantage of having two tabs open in your browser: one for nanogolive (for further navigation) and other for your selected new story.
Updated :
Monoclonal antibodies could boost your portfolio.
Publ.Date : Mon, 06 Sep 2010 04:30:20 -0700
Seattle Genetics, Inc. announced that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc. The milestone was triggered by Agensys' initiation of a phase I trial for AGS-16M8F, an ADC for the treatment of cancer utilizing Seattle Genetics' technology.
Publ.Date : Sun, 05 Sep 2010 20:42:31 -0700
From growing new bone to advances in post-traumatic stress disorder to sophisticated prosthetic legs for bicycling and rock climbing, Cleveland hospitals are contributing to medical advances spurred by the war in Iraq.
Publ.Date : Sun, 05 Sep 2010 00:58:00 -0700
Though shares of Celldex Therapeutics Inc. plunged 26.2 percent on the news, President and CEO Anthony Marucci sees Pfizer Inc.'s decision to return rights to brain cancer vaccine CDX-110 (rindopepimut) as a positive event for his company.
Publ.Date : Fri, 03 Sep 2010 18:00:12 -0700
Wayne C. Koff, Chief Scientific Officer and Senior Vice President of Research and Development (R&D) at the International AIDS Vaccine Initiative (IAVI.org), will give the keynote presentation titled "Future Directions in AIDS Vaccine Development: The Decade Ahead" at the 8th Annual Vaccines: All Things Considered Conference to be held this year in Washington, DC on Nov. 8-9, 2010 by GTCbio. Dr...
Publ.Date : Mon, 06 Sep 2010 07:42:16 -0700
AstraZeneca's RSV candidate, motavizumab, received yet another Complete Response Letter from the FDA.
Publ.Date : Mon, 06 Sep 2010 01:27:45 -0700
According to a new study, children who survive cancer are at a higher risk of cancer later in life or may die early of other cause. The study included almost 900 young cancer survivors treated at Sydney Children's Hospital, from 1972 to 1999, alongside new cancer cases and early deaths. The risk of cancer was five times higher in childhood cancer survivors, the results showed, compared with the ...
Publ.Date : Sun, 05 Sep 2010 19:57:12 -0700
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/257d46/alzheimers_diseas) has announced the addition of the "Alzheimers Disease Immunotherapy Pipeline: Vaccines, Therapeutic Antibodies and Emerging Strategies - 2010" report to their offering. Current drug treatments for Alzheimers Disease (AD) are dominated by two drug classes ...
Publ.Date : Mon, 06 Sep 2010 10:14:06 -0700
Many youths appear resistant to treatment from the onset of a severe asthmatic condition. Why? Simply put, many have been wrongly diagnosed or caretakers have not followed asthma treatment guidelines properly. There is no one cure-all for this condition that is a chronic, or long-term lung disease that inflames and narrows the airways...
Publ.Date : Fri, 03 Sep 2010 14:41:31 -0700
MorphoSys AG announced a new proprietary development programme against novel infectious disease targets.
Publ.Date : Mon, 06 Sep 2010 00:42:31 -0700
|
|
|
advertisement
Advertise with nanogolive
Advertise your Antibody Research products, services, events or job vacancies with nanogolive.
Learn More.
|
Life Science Jobs
